JP2020502225A - トリアジントリオン誘導体、ならびにニューロトロフィン受容体および受容体型チロシンキナーゼのモジュレーターとしてのその使用。 - Google Patents

トリアジントリオン誘導体、ならびにニューロトロフィン受容体および受容体型チロシンキナーゼのモジュレーターとしてのその使用。 Download PDF

Info

Publication number
JP2020502225A
JP2020502225A JP2019534090A JP2019534090A JP2020502225A JP 2020502225 A JP2020502225 A JP 2020502225A JP 2019534090 A JP2019534090 A JP 2019534090A JP 2019534090 A JP2019534090 A JP 2019534090A JP 2020502225 A JP2020502225 A JP 2020502225A
Authority
JP
Japan
Prior art keywords
compound
disease
pharmaceutically acceptable
alkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019534090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502225A5 (https=
Inventor
ヌーデバル，グンナー
フォーシェル，ポンタス
サンディン，ヨハン
Original Assignee
アルゼキュア ファーマ アーべー
アルゼキュア ファーマ アーべー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルゼキュア ファーマ アーべー, アルゼキュア ファーマ アーべー filed Critical アルゼキュア ファーマ アーべー
Publication of JP2020502225A publication Critical patent/JP2020502225A/ja
Publication of JP2020502225A5 publication Critical patent/JP2020502225A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019534090A 2016-12-21 2017-12-21 トリアジントリオン誘導体、ならびにニューロトロフィン受容体および受容体型チロシンキナーゼのモジュレーターとしてのその使用。 Pending JP2020502225A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1651706-2 2016-12-21
SE1651706 2016-12-21
PCT/GB2017/053868 WO2018115891A1 (en) 2016-12-21 2017-12-21 Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases

Publications (2)

Publication Number Publication Date
JP2020502225A true JP2020502225A (ja) 2020-01-23
JP2020502225A5 JP2020502225A5 (https=) 2021-02-04

Family

ID=60923799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019534090A Pending JP2020502225A (ja) 2016-12-21 2017-12-21 トリアジントリオン誘導体、ならびにニューロトロフィン受容体および受容体型チロシンキナーゼのモジュレーターとしてのその使用。

Country Status (12)

Country Link
US (1) US20200113910A1 (https=)
EP (1) EP3558320A1 (https=)
JP (1) JP2020502225A (https=)
KR (1) KR20190098982A (https=)
CN (1) CN110167558A (https=)
AU (1) AU2017380583A1 (https=)
BR (1) BR112019012709A2 (https=)
CA (1) CA3046289A1 (https=)
IL (1) IL267086A (https=)
MX (1) MX2019007606A (https=)
RU (1) RU2019120431A (https=)
WO (1) WO2018115891A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52415A (fr) 2018-02-26 2021-01-06 AlzeCure Pharma AB Dérivés de triazine pour le traitement de maladies associées à des neurotrophines
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201912404D0 (en) * 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
CN113893334A (zh) * 2021-10-19 2022-01-07 内蒙古医科大学第二附属医院 基于cAMP/PKA-CREB-BDNF信号通路的七氟烷影响抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718799A1 (de) 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
KR101457027B1 (ko) * 2009-06-09 2014-10-31 캘리포니아 캐피탈 에쿼티, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
CN103180297A (zh) * 2009-12-11 2013-06-26 基因密码公司 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
F. ZHANG ET AL., JOURNAL OF CLINICAL NEUROSCIENCE, vol. 19, no. 7, JPN6022004399, 2012, pages 946 - 949, ISSN: 0004701525 *
K. SUZUKI ET AL., FEBS OPEN BIO, vol. 6, no. 5, JPN6022004398, 2016, pages 461 - 468, ISSN: 0004701524 *
L. GASPARINI, TRENDS IN NEUROSCIENCES, vol. 26, no. 8, JPN6022004401, 2003, pages 404 - 406, ISSN: 0004701526 *

Also Published As

Publication number Publication date
CN110167558A (zh) 2019-08-23
IL267086A (en) 2019-08-29
RU2019120431A (ru) 2021-01-22
BR112019012709A2 (pt) 2019-11-26
RU2019120431A3 (https=) 2021-03-09
CA3046289A1 (en) 2018-06-28
WO2018115891A1 (en) 2018-06-28
EP3558320A1 (en) 2019-10-30
US20200113910A1 (en) 2020-04-16
MX2019007606A (es) 2020-07-29
AU2017380583A1 (en) 2019-06-27
KR20190098982A (ko) 2019-08-23

Similar Documents

Publication Publication Date Title
US12209071B2 (en) Triazine derivatives for treating diseases relating to neurotrophins
JP2020502225A (ja) トリアジントリオン誘導体、ならびにニューロトロフィン受容体および受容体型チロシンキナーゼのモジュレーターとしてのその使用。
TWI423978B (zh) 作為ｈｍ７４ａ同效劑之嘌呤酮衍生物（二）
CN105189452B (zh) 苯基亚甲基胍衍生物以及其用于蛋白质错误折叠疾病的治疗用途
CN110914253B (zh) 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
JP6781148B2 (ja) ヒドロキシステロイド化合物、それらの中間体、それらの調製方法、組成物および使用
CN116348468A (zh) Cftr调节剂化合物、组合物及其用途
US20210269442A1 (en) Fused ring derivative used as fgfr4 inhibitor
CA3195127A1 (en) Rev-erb agonists
CN120731207A (zh) 6-烷氧基吡唑并嘧啶化合物及其药学用途
CA3147623A1 (en) Triazine derivatives for treating diseases relating to neurotrophins
JP2023507180A (ja) Ｏｇａ阻害剤化合物
US8314092B2 (en) Substituted [(5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists
KR20210028649A (ko) Trk 수용체의 조절제로서의 4-치환된 페닐-1,3,5-트리아진 유도체
WO2023011608A1 (zh) 含三并环类衍生物调节剂、其制备方法和应用
RU2816837C2 (ru) Производные триазина для лечения заболеваний, связанных с нейротрофинами
KR102381002B1 (ko) 벤조산 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물
JP2026067907A (ja) 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
HK40033844B (en) Triazine derivatives for treating diseases relating to neurotrophins
HK40033844A (en) Triazine derivatives for treating diseases relating to neurotrophins
WO2021075477A1 (ja) 運動神経細胞変性阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220913